Discover Astex
Our Mission & Values
Our Leadership Team
UK – Discovery Research
Jeremy Carmichael
Gianni Chessari
Harren Jhoti
Michelle Jones
Neil Jones
John Lyons
Chris Murray
Marc O’Reilly
David Rees
Nicola Wallis
Nicola Wilsher
USA – Product Development
Martin Buckland
Harold N. Keer
Nipun Davar
Beloo Mirakhur
Talat Ashraf
D. Jeffery Grimes
Joseph Iovino
Samuel Jason
Daisy Leung
Aram Oganesian
Pratibha Sampeur
Sonia Souza
Nancy Worrell
Our History
Corporate Social Responsibility
R&D
Clinical Pipeline
Proprietary Products and Programs
Oral Decitabine and Cedazuridine (ASTX727) (Hematological Malignancies)
Tolinapant (ASTX660) – Solid Tumors & Lymphomas
ASTX029 Extracellular Signal-Related Protein Kinases (ERK 1/2) Inhibitor (Solid Tumors)
ASTX295 Oral Murine Double Minute 2 (MDM2) antagonist (Solid Tumors)
Azacitidine and Cedazuridine (ASTX030) Oral DNMT inhibitor (Hematological Malignancies)
TAS1440 Oral LSD1 inhibitor (Hematological Malignancies)
TAS1553 Oral small molecule ribonucleotide reductase (RNR) inhibitor (Hematological Malignancies)
Partnered Products and Programs
Kisqali
®
(ribociclib) CDK4/6 inhibitor (Oncology)
Balversa
®
(erdafitinib) FGFr inhibitor (Oncology)
Truqap™ PKB/Akt Inhibitor (Oncology)
Multiple Targets and Therapeutic Areas
Pyramid™ Discovery Platform
Oncology and CNS Discovery
Sustaining Innovation Postdocs
Partnering
Our People & Culture
Career Opportunities
Media
Press Releases
Conferences & Meetings
Presentations & Publications
Interactive Scientific Resources
Interactive Software
Astex in the News
Contact
Search
Menu
Menu
You are here:
Home
1
/
Search results for ""
New Search
If you are not happy with the results below please do another search
Scroll to top
